RPT904
Phase 2Small molecule
RPT904 is one of 11 small molecule programs targeting Food Allergy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Food Allergy
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaApproved
Singulair
OOrganon and Co
Approved
Xolair
RochePhase 3
Imbruvica
PPharmacyclics LLC.
Approved
DUPIXENT
RegeneronPhase 3
Ligelizumab
NovartisPhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Cibinqo
PfizerPhase 1
Epiceram
SStanford University
Phase 3
Linvoseltamab
RegeneronPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RPT904. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRAPT Therapeutics, Inc.